Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 23

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

372

HTML

2768

Figures (1-2)

193

Tables (1-3)

199

Sum=3532

Jun 21, 2008 (publication date) through Dec 25, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Jun 21, 2008; 14(23): 3750-3753
Published online Jun 21, 2008. doi: 10.3748/wjg.14.3750

Full Size Figure Download Figure

Figure 1 Distribution of preoperative serum CA19-9 levels. The horizon marker is set according to the cut-off point of CA19-9 (353.15 U/mL).

Citation: Zhang S, Wang YM, Sun CD, Lu Y, Wu LQ. Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. World J Gastroenterol 2008; 14(23): 3750-3753
URL: https://www.wjgnet.com/1007-9327/full/v14/i23/3750.htm
DOI: https://dx.doi.org/10.3748/wjg.14.3750